Glucagon enhanced insulin absorption in Diabetes Mellitus type 1

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-502455-57-01

Enrollment

Registered

2023-03-29

Start date

2023-06-20

Completion date

2023-12-22

Last updated

2023-03-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes mellitus type 1

Brief summary

Area under the glucose curve for the first 60 minutes.

Detailed description

Area under glucose curve for any other time span during the first 3 hours., Area under the insulin curve for any time span during the first 3 hours, Area under the glucagon curve for any time span during thefirst 3 hours., Pharmacokinetic estimates for insulin., Pharmacokinetic estimates for glucagon., Thermal camera measurements., Laser doppler flowmetry measurements.

Interventions

DRUGGLUCAGON

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Area under the glucose curve for the first 60 minutes.	—

Secondary

Measure	Time frame
Area under glucose curve for any other time span during the first 3 hours., Area under the insulin curve for any time span during the first 3 hours, Area under the glucagon curve for any time span during thefirst 3 hours., Pharmacokinetic estimates for insulin., Pharmacokinetic estimates for glucagon., Thermal camera measurements., Laser doppler flowmetry measurements.	—

Countries

Norway

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026